Non-Hodgkin

Treatment outcomes in lymphomas are heavily influenced by gut microbiota and the range and types of bacteria strains. Comparing patient case data has reported on how high diversity of gut bacteria improves stem cell therapy success results including reduced overall risks. Crucially, therapy failure is linked to poor gut microbiota and in particular deficiency or absence of blautia and akkermansia bacteria types. Some necessary oncology treatments reduce levels of these bacteria as do antibiotics.

Recent strudies have reported large advantages in having higher levels of vitamin D3. An active supplementation trial in Hodgkin Lymphoma was able to correct D3 levels in about a quarter of patients, and reports over 60% improved recurrence free response during rituximab immunotherapy. This would be a much larger effect if comparing full normal levels with clearly deficient patients. Mechanisms around vitamin D3 differ slightly in Non Hodgkin but these studies are highly relevant.

Also with rituximab, significant numbers of previously and refractory treated patients have benefitted when yeast derived beta glucans have been added in oncology increasing the response rate to oncology drugs and increasing immune system activity in patients. Whilst these trials can be with patented compounds, many of the effects reported have also been seen in 1,3/1,6 beta glucan supplements. Successful treatment for lymphomas relies strongly on how quickly new white blood cells can be produced. The Nicotinamide Riboside variant of vitamin B3 has been extensively studied in anti-aging science for its ability to increase cellular mitochondrial health. Now, there are is remarkable pre-clinical evidence that this vitamin can substantially increase stem cell activity that drives production of new white blood cells. Related, nicotinamide B3 has reached phase II for reducing incidence of melanoma in leukemia patients.

Systemic acute type inflammation is associated with most cancers, and often measured with c-reactive protein. Supplements including curcumin, garlic and an anti-inflammatory functional food regime are all evidence based interventions. Re-balancing immune system inflammation levels, the neutrophil-to-lymphocyte ratio and improving low platelet count both reduce risks quite substantially. A natrual immune modulator, Astragalus has evidence of supporting both before and during oncology treatments.

The so called Th1/Th2 immune system balance is strongly linked to the progression in NHL and to treatment resistance. Molecular iodine solutions are emerging in this area in breast cancer management, seen boosting Th1 anti tumor activity and helping suppress over active Th2 used in resistance. This has improved results in surgery plus chemotherapy and may support increased responses during immunotherapy (see Supplement Library). For immunotherapy the presence of high sodium levels is now identfied as a key marker for success in other cancers. Inosine has also been linked to better outcomes. Also in other cancers, AM treatment programs are substantially more effective that PM/evening sessions

For non hodgkin patients treated with tyrosine kinase inhibitors such as ibrutinib, a 2025 large analysis across nearly 1500 cases showed that stain use confers a risk reduction of over 60%. Its to be proven if this effect would be seen in the other 71% of patients who were not on statins, or a sub group of those. But a remarkable effect none the less.

Subscribe to the site for Pathfinder ANALYSIS and helpful GUIDE. Build you personal plan with confidence.

Click the IMAGE to view the library entry

Akkermansia can be effectively increased with functional foods such as walnuts and oat glucans

Low or no akkermansia and blautia gut bacteria level linked with treatment failure
Oncology treatments and antibiotics both reduce levels and diversity of bacteria
Diversity of gut microbiota has extensive research linked to better prognosis

Lower microbial gene richness, a lower abundance of the genus Blautia, and a lower abundance of Akkermansia muciniphila, early post-aHSCT was observed in those who developed aGVHD. Myeloablative conditioning was associated with aGVHD along with a reduction in gene richness and abundance of Blautia and A.muciniphila. These results confirm low diversity and Blautia being associated with aGVHD. Crucially, we add that pretransplant conditioning [chemo/radiotherapy] is associated with changes in gut microbiota. Investigations are warranted to determine the interplay of gut microbiota and conditi...

Beta glucans protect and balance immune system activity improving outcomes

Including a pharma grade beta glucan boosts response rate about 50%
About a third of the patient group were “non responders” with rituximab alone
Significantly activates immune system response and enables greater drug activity

These IPD responses are not only important for the immune effector mechanisms required for combination with antitumor antibodies, like R, but also for the activity of immune checkpoint inhibitors. IPGG has been combined with pembrolizumab in solid tumors (NCT02981303), and pre- and on-treatment biopsies demonstrate increased M1-macrophage and activated T-cell tumor infiltration. These data support a trial exploring the triplet combination of R-IPGG with checkpoint inhibition in r/r indolent B-NHL.

Vitamin D3 and its immune system health actions are key, higher doses being trialed in oncology

A clinical intervention trial of high dose D3 with immunotherapy, level correction and during oncology
Over 90% initially insufficent, which was reduced to around 70%, high BMI limits serum D3 levels
Over 60% improved event free survival reported, and that was conservative

We analyzed the impact of 25(OH)D levels on event-free survival in patients treated with Rituximab… 25(OH)D levels below 20 ng/mL at diagnosis and IPI were independently associated with inferior EFS. Moreover, patients with normalized 25(OH)D levels following supplementation showed better EFS than patients with persistently deficient/insufficient 25(OH)D levels. Our study provides the first evidence that achievement of normal 25(OH)D levels after vitamin D3 supplementation is associated with improved outcome in patients with DLBCL and deficient/insufficient 25(OH)D levels when receivi...

Vitamin B3 in several forms shows protective effects in cancers

Vitamin B3 riboside variant accelerates activity of hematopoietic stem cells
Large protective effect in mouse model gave dramatically higher survival
B3 is widely available and has supporting evidence in other cancers

NR dietary supplementation results in a significantly enlarged pool of progenitors, without concurrent HSC exhaustion, improves survival by 80%, and accelerates blood recovery after murine lethal irradiation and limiting-HSC transplantation….Our work demonstrates for the first time a positive effect of NAD⁺-boosting strategies on the most primitive blood stem cells, establishing a link between HSC mitochondrial stress, mitophagy, and stem-cell fate decision, and unveiling the potential of NR to improve recovery of patients suffering from hematological failure including post...

Alpha Ketoglutarate is emerging in oncology particularly for enhancing immune system activity during immunotherapy

Lymphoma tumors cells upregulated glutamine and low alpha-ketoglutarate levels drive growth
Increasing AKG levels strongly suppresses glutamine uptake showing very striking results in a mouse model
Effects in health and anti-aging science show metabolic and anti-inflammatory benefits

Notably, glutamate, glutamine, and α-KG were the critical metabolites in glutamine metabolism. Clinical data analysis identified that high glutamine concentrations and low decreased α-KG were associated with poor prognosis in DLBCL patients. Subsequently, dimethyl α-ketoglutarate (DM-αKG) was used to reverse glutamine metabolism and increase α-KG concentration. In vitro studies showed that DM-αKG treatment significantly inhibited cell proliferation of DLBCL cells both in vitro and in vivo

Lactoferrin increases iron balance and reduces anemia rates, countering cancers use of iron

Cancer related elevated ferritin strongly links to progression risk
Patients with relatively lower levels have 42% risk reductions
Even more beneficial progression risk reduction of 57%

Increased levels of serum ferritin found in patients with malignancy could exert adverse effects on the host immune response and perhaps have an inhibitory effect on hematopoiesis.33 Other studies have suggested that high ferritin expression in tumor tissues and elevated serum levels were the result of inflammation and oxidative stress and improved resistance to oxidative stress by interfering with the cellular antioxidant system. Malignant tumors might manipulate the body’s inflammation process to promote their own angiogenic growth, which could lead to disease progression in NHL.</p...

Citrus Pectin removes heavy metals such as copper and has its own anti-cancer mechanisms

Elevated circulating copper in about 1/5 of patients
Higher copper levels are reported as significant risk factors
Many cancers have high copper/ low zinc showing increased progression

The reason for the association between the high serum copper levels and adverse prognosis is unknown. We hypothesized that interleukin-6 is secreted primarily by non-neoplastic cells at MF skin sites, leading to release of copper by the liver. Local production of interleukin-6 at the lesion sites might conceivably also promote neoplastic cell progression by stimulation of the STAT3 pathway. Further studies on the relationship between activated tumor-associated macrophages, serum copper levels, interleukin-6, or C-reactive protein and prognosis might be informative.

Berberine evidence in metabolic health may help counter cancers use of lipids and sugars to grow

Analysis shows on average a 60% elevation in free fatty acids (lipids)
Lower levels compared to higher reported to halve the overall risk
Berberine actions include both free fatty acid /lipid and glucose control

We demonstrated the clinical significance of pretreatment serum FFA levels in patients with newly diagnosed DLBCL. Our results indicated that a high pretreatment serum FFA level was associated with adverse features such as the presence of B symptoms, higher serum LDH levels, >1 extranodal sites, and a higher IPI score. Survival analysis also demonstrated that higher pretreatment serum FFAs were associated with lower survival in untreated DLBCL patients. These findings indicate that abnormal lipid metabolism may contribute to DLBCL development and progression

Curcumin has evidence for reducing levels of systemic inflammation used by cancers

Lower inflammation indicated by c-reactive protein lowers risk
Patient case data shows over 50% risk overall reduction
Even larger effect on risk of progression, almost halved by low CRP

In the present study, a significant association between elevated CRP and poor outcome of 477 DLBCL patients at two Austrian centres could be confirmed. Univariate analysis, as well as multivariate analysis, identified the pretreatment CRP level as a useful prognostic marker of 5-year OS and 5-year-DFS. Furthermore, by integrating the CRP levels in the well-established R-IPI score improved the predictive ability of this score by 4%. Beyond the results of our study that focuses on the CRP levels before treatment initiation

Astragalus actions include protecting and balancing immune responses often with clear effects reported

Immune system inflammation marker NLR linked to risk
The 3/4 of patients below the cut-off had 35% reduced risk levels
Low platelet count is a similar risk factor for NHL progression

Our result revealed that the optimal cut-off for NLR was 6. NLR predicted both OS and PFS of the patients with de novo DLBCL. NLR is a simple and useful scale and it might be a useful marker for prediction of patients’ survival or disease progression in patients with de novo DLBCL. The optimal cutoff for NLR was 6. NLR(6) was associated with overall survival(OS)(HR 1.76) and progression free survival(PFS) (HR 2.66), either. Multivariate analysis identified NLR(6) remained as a significant factor affecting PFS (hazard ratio: 1.53).

Red Yeast Rice or prescription statin can reduce overall risks in small lymphocytic lymphoma

Users of statins during treatment show strongly improved outcomes
Strikingly large risk reduction level of 61%, progression free risk reduced 27%
Small lymphocytic lymphoma treated with TKI ibrutinib

This study provides valuable insights into the associations of baseline statin use with survival and adverse event outcomes in patients with CLL/SLL initiating contemporary treatment regimens. The findings revealed a statistically significant association between statin utilization and improved OS, PFS, and cancer-specific survival. The latter suggests a potential disease-modifying effect of statins in this patient population. No significant associations were observed between statin use and the occurrence of grade ≥3 adverse events. Notably, statin use emerged as a consistent positive prog...

Support us and get our essential pathfinder GUIDE. Impacts Analysis, Usage and doses, EXAMPLE plan and supporting comments

GUIDE

Pathfinder Element	Risk Reduction Factor	Anti-Metastatic	Reduces Side Effects	Research Study
Aspirin	>50%	Yes	Maybe	Link
Vitamin D3	>50%	Yes	Maybe	Link
Red yeast rice/ statin	>50%	Probably	Maybe	Link
Beta Glucan	26 - 50%	Yes	Yes	Link
Antihistamines with Immunotherapy	26 - 50%	Probably	Probably	Link
Astragalus	Indirect - High	Yes	Yes	Link
Citrus Pectin	Indirect - High	Probably	Yes	Link
Gut microbiome / Akkermansia	Indirect - High	Probably	Yes	Link
Lactoferrin	Indirect - High	Probably	Yes	Link
Vitamin B3	Indirect - High	Maybe		Link
Alpha ketoglutarate	Indirect - High		Maybe	Link
Berberine	Indirect - Moderate	Maybe	Maybe	Link
Curcumin	Indirect - Moderate	Maybe	Maybe	Link

Plan Item	Cancers	Background Details	Trial Doses Under Supervision	References
Antihistamines	Breast, TNBC, Prostate, Lung, Colorectal, Kidney, Liver, Gastric, Ovarian, Cervical, Pancreatic, Melanoma, Lymphoma, Esophageal, Bladder	Research indicates desloratadine for localized cancers or loratadine for metastatic. There are examples of ebastine or other alternatives in certain cases. Growing research evidence indicates improved oncology responses. Taken between meals. Low histamine before and during treatment is beneficial.	Active use in clinical trials is still in early phase, follow the dose recommendation for instance 5mg daily unless under medical supervision where higher 10mg doses are frequent
Aspirin	Breast, TNBC, Prostate, Lung, Colorectal, Kidney, Liver, Ovarian, Cervical, Endometrial, Pancreatic, Melanoma, Myeloma, Head and Neck, Bladder, Gallbladder, Non Melanoma Skin, Gastric	Use of low dose 75 or 81mg "baby" aspirin is reported to benefit many cancer types across an average study group, and even all cause mortality. There are some indications of specific "responders" for instance those with existing inflammatory conditions or certain gene expressions. With food.	In a colorectal cancer trial responders were tied to the expression of particular genes (PI3KA). Doses were 160mg	LINK
Astragalus	Breast, TNBC, Lung, Colorectal, Liver, Gastric, Cervical, Endometrial, Pancreatic, Prostate, Kidney, Ovarian, Glioblastoma, Non Hodgkin, Lymphoma, Leukemia, Myeloma, Head and Neck, Bladder, Gallbladder, Thyroid	A typical astraglaus membranaceus supplement may have 50mg of astragaloside IV the main active compound. Its possible with meals can reduce any stomach upset. Use of a standard dose to help immune system balance before treatment.	Here, Astragalus is added to standard oncology in lung cancer Doses are 2-3 tablets of 250mg AMe (Solgar, NJ, USA) minimum for 6 months in this example	LINK
Beta Glucans	TNBC, Lung, Liver, Gastric, Cervical, Pancreatic, Melanoma, Non Hodgkin, Lymphoma, Leukemia	There are many options for mushroom or yeast 1,3/1,6 glucan and branded products include California Gold Immune Defense/Wellmune, AHCC, Biogen/ Yestimun, ImmiFlex, IP6 and many more. A pharma grade product, odetiglucan, is continuing in trials. Take on an empty stomach. Use a standard dose to help balance the immune system before starting treatments.	AHCC is used at 3x1g per day over several months during treatment. Beta glucans are used at 1-2g per day and higher.	LINK
Danshen	Breast, Prostate, Lung, Colorectal, Liver, Leukemia, Myeloma, Bladder	The most common chinese herbal medicine in oncology, also known as red sage. Premium brands such as MCS may recommend 1g twice daily as an ongoing dose. Its possible with meals can reduce any stomach upset. Start a standard dose a couple of weeks before treatment to help balance the immune system.	3 x1g daily between meals , over at least 90 days ideally longer to get maximum benefits according to reported patient outcomes, though even shorter dose period reduced risk	LINK
Green Coffee Extract	Glioblastoma	Supplements vary in terms of their chlorogenic acid content, it can be up to 50%. Quality brand might specify this level under their recommended intake. High dose commercial brands may be over 1000mg total, take before meals.	Analysis across trials reports metabolic health benefits start are higher at >500mg or daily. High chlorogenic acid content supplements eg Svetol have been trialed safely for 12 weeks at 200mg x 5 daily dose. As always, be aware of possible drug interactions	LINK
Red Yeast Rice Or statin	Breast, TNBC, Prostate, Lung, Colorectal, Kidney, Liver, Gastric, Ovarian, Cervical, Endometrial, Melanoma, Leukemia, Myeloma, Head and Neck, Esophageal	Red yeast rice is equivalent to lovastatin. Doses are essentially on the products, and there are many premium brands with guaranteed level of monokolin k around 3mg. A common theme is findings is those with improved cholesterol are "responders". With meals. Start cholesterol and inflammation reducing statins early.	Trial data is often case studies with multiple statins where lovastatin has average effects. Often atorvastatin and sometimes simvastatin come out on top. Research ususally reports intermediate doses ( 10-20mg) are effective but there are examples indicating higher doses under supervision.	LINK
Turkey Tail	Lung, Colorectal, Kidney, Liver, Gastric	A typical premium supplement such as MCS recommend 700mg twice daily with food. Mushroom based glucans can help balance immune response so start them before your treatment.	Pharma grade turkey tail, e.g PSP/ PSK/ Krestin is typically used at 3x 1g daily during oncology, up to 36 months and more. Trials in breast cancer have also used 3,6 and 9g daily regimes in 6 week periods	LINK
Vitamin D3	Breast, TNBC, Prostate, Lung, Colorectal, Gastric, Ovarian, Pancreatic, Glioblastoma, Melanoma, Non Hodgkin, Lymphoma, Leukemia, Myeloma, Head and Neck, Esophageal, Bladder	High dose commercial formulae can be 10,000IU. Which might be achieved by as little as 10 to 20 minutes in sunshine. Vitamin K2 is advised with D3. Take with some food containing fat. Its important to ramp these up before oncology treatments, and sustain the higher levels over time. Add magnesium for best absorption and metabolism.	The VITAL trial used 2000IU and discussed the potential of higher doses to increase responders especially higher BMI/ body weight. Whilst in prostate cancer there are trials demonstrating at least 10,000IU is required to see activity reducing PSA levels	LINK
Melatonin	Breast, TNBC, Prostate, Lung, Kidney, Liver, Ovarian, Cervical, Endometrial, Pancreatic, Glioblastoma	Commonly used in 10 to 40mg daily range no reported side effects, typically an hour before sleep.	Moderate and high dose trials report no significant side effects even at 1000mg daily	LINK
Citrus Pectin	Breast, TNBC, Prostate, Lung, Colorectal, Kidney, Liver, Ovarian, Cervical, Endometrial, Pancreatic, Non Hodgkin, Leukemia, Myeloma, Head and Neck, Esophageal, Bladder, Gallbladder, Thyroid, Gastric	Trials use a recommended dose up to 5g x3 daily and no significant side effects. Taken 30 minutes before or 90 minutes after food. Ideally, start PectaClear or similar products at least 4 week before treatment to reduce heavy metals. But sustain zinc with supplementation	Even in children age 5 to 12 the daily regime 3 x 5g was safe and effective for heavy metal chelation	LINK
Soy Isoflavones	Breast, Prostate, TNBC	Often dietary sources, tofu and soy based and no evidence of side effects. Supplements generally with food.	In a clinical trial setting up to 900mg with no issues	LINK
Fermented Wheatgerm	Prostate, Colorectal, Melanoma	Trials are with Avemar brand products with no significant safety concerns reported	Typical dose regimes may be aroung 9g daily over longer time periods for instance 12 months	LINK
Iodine	Breast, TNBC	General usage around 1000mcg or 1mg generally with food	Successful pilot studies in breast cancer use 5mg molecular Iodine daily for the duration of therapy	LINK
Lactoferrin	Breast, TNBC, Prostate, Lung, Colorectal, Kidney, Liver, Gastric, Ovarian, Cervical, Endometrial, Pancreatic, Glioblastoma, Melanoma, Non Hodgkin, Lymphoma, Leukemia, Myeloma, Head and Neck, Bladder, Esophageal, Gallbladder, Thyroid	200mg typical use daily , eg 10ml liposomal formula ideally 30 minutes before meals or 2 hours after. No side effects of note. Start this immediately to achieve and maintain healthy iron absorption, avoid deficiencies and reduce cancer related ferritin levels.	During oncology doses of up to 3g to 9g daily, even higher, have been used with significant side effects	LINK
Selenium	Breast, Lung, Kidney, Ovarian, Cervical, Endometrial, Pancreatic, Melanoma, Head and Neck	Supplements are 200ug doses and similar amounts from about 3 brazil nuts. Start buildin gup your levels immediately and keep them high during oncology. Selenium toxicity is a consideration for high doses over time, so seek medical advice. Ideally taken with meals.	This trial used 2500 to 4000ug 2x daily for 14 days then once daily in kidney cancer with no dose limiting toxicity	LINK
Vitamin B3	Liver, Gastric, Glioblastoma, Non Hodgkin, Lymphoma, Leukemia, Non Melanoma Skin	Typically 500mg for nicotinamide (niacinamide) form of B3 taken ideally with meals	Do not differ from standard doses, here 500mg twice daily related to skin cancer	LINK
Akkermansia	Breast, TNBC, Prostate, Lung, Kidney, Liver, Ovarian, Cervical, Pancreatic, Non Hodgkin, Lymphoma, Leukemia, Myeloma, Head and Neck, Gastric	Commercial products may be at 10B CFU typically 30 minutes before or 2 hours after food. Ramp up levels with diet and moderate supplementation before treatments, especially immunotherapy.	Under development. Results in oncology indicate this is one of many helpful guy bacteria. careful consideration and particularly following use of antibiotics. Diversity is crucial.	LINK
Berberine	Kidney, Liver, Cervical, Pancreatic, Non Hodgkin, Leukemia, Myeloma, Head and Neck, Esophageal, Gallbladder, Thyroid, Non Melanoma Skin, Melanoma, Bladder	A natural anti-diabetic used frequently at 400mg daily and above, shortly before meals	In metabolic health trials frequentlu use up to 500mg at 3 times daily .	LINK
Curcumin	Colorectal, Liver, Non Hodgkin, Myeloma, Bladder, Gallbladder, Non Melanoma Skin, TNBC, Breast, Prostate, Lung, Kidney, Gastric, Ovarian, Cervical, Endometrial, Glioblastoma, Melanoma, Lymphoma, Leukemia, Head and Neck, Thyroid	Doses from 500mg to 2000mg frequently seen. Piperine fron black pepper improves absorption, highly bioavailable formulae are available. Ideally with a meal containing fat.	Higher doses in trials are frequently 2 of 4 g daily (+40 mg piperine) during oncology for instance here at 3 periods of 30 days	LINK
Quercetin	Glioblastoma, Myeloma	Can be found in a healty diet. Supplements often 500 or 1000mg and can be taken with tocotrienols for enhanced absorption, a form of vitamin E . Some evidence that Quercetin should be pulsed on/off.	Clincial trials have safely used up to 5g daily in adults, and 1 to 4g for rare forms of paediatric anemia	LINK
Urolithin A	Prostate, Lung, Colorectal, Kidney, Gastric, Glioblastoma, Melanoma, Myeloma, Gallbladder, Head and Neck	Typical commercial brands run at 500mg once or twice daily, with or without food, some brands suggest with meals	Trials eg in anti-aging science use the same dose range	LINK
Oat and Egg Functional Food	Breast, TNBC, Prostate, Lung, Colorectal, Kidney, Liver, Cervical, Pancreatic, Glioblastoma, Melanoma, Head and Neck, Gallbladder	Follow supplier guidance on dosage and use. https://shop.lantmannenfunctionalfoods.com/? Lowering tumor fluid pressure helps treatments work, start these before your treatment if possible. Use egg based salovum for short term "pulse" during therapy and oat products for sustained use over longer time periods	This trial in glioblastoma used 16g egg based Salovum four times daily. It discusses lowering that regime in follow on trials.	LINK
Coffee	Breast, Prostate, Colorectal, Liver, Non Melanoma Skin	Most dietary studies use standard 8oz servings as a guide. In many cases the findings are that benfits increase with intake. But in some cases such as prostate cancer there are important details in the PATHFINDER	No, but chlorogenic acid and, separately, green coffee extracts are used at 400mg and up to 2000mg
Flax	TNBC, Ovarian	Crushed flaxseed alone or in foods around 1/4 cup daily	Doses up to 50g daily in clinical trials for various diseases. Here a fairly typical 30g regime in inflammatory liver diseases	LINK
Propolis	Breast	Typical supplements range from 400 to 1000mg	Here 400mg x3 daily help recovery from radiotherapy	LINK
Walnuts	Prostate, Colorectal, Melanoma, Head and Neck	Dietary food item shown even at low useage to be helpful even at a few oz per week	Here, 2oz (56g) daily showed measurable activity in breast cancer	LINK
Mushroom	Prostate	Both dietary sources and many commercial supplements normally taken with food	In this example some patients saw responses between 8 and 14g daily of button mushroom extract	LINK
Zinc	Kidney, Ovarian, Cervical, Endometrial, Head and Neck, Non Melanoma Skin	Commercial supplements vary considerably . Moderate 20mg range generally advised	No
Intravenous HIgh Dose Vitamin C	Pancreatic, Glioblastoma	Commercial supplements vary. A moderate range around 20mg with food is generally accepted as safe.	Same as general guidance
Alpha Ketoglutarate	Melanoma, Kidney, TNBC, Non Hodgkin, Lymphoma	Typical usage is 1000mg daily with or without food, safety is good. Its especially important to ramp up and sustain your levels for maximum immunotherapy responses.	Larger doses of several grams have been safely used in various trials including here in bone disease at 6g daily	LINK
Horse Chestnut (Escin)	Thyroid	Common 300 to 600mg supplements contain 50 to 120mg of active compound, escin taken with food	Escin up to 150mg daily in vascular health. In oncology 0.6 mg/kg/day for 9 days, intravenous injection has been used, high absorption premium supplement would reacj this level	LINK

There can be an active suveillance phase with Non Hodgkins, and advancing disease is often treated with chemotherapy plus targeted drugs like rituximab. And in some cases a variety of other immunotherapy and targeted agents may be used, even stem cell transplants.

Your PATHFINDER brings together research that may help slow down early phase progression considerably. And, with advancing disease, maximize the effects of chemotherapy, targeted drug treatments or immunotherapy. The IMPACTS tab summarizes these and can lead to Many more Good days by helping these treatments work, reducing your risk for progression and by easing treatment side effects. If you do elect both chemotherapy and targeted drugs, you can continue to look for ways to increase the results and reduce possible toxicities;

Be sure to fully read and absorb the PATHFINDER and its Impacts summary
If you have metastatic sites take a look into the corresponding Pathfinder for those too, for inspiration.
Use the Supplement Library Index and filter on “Chemotherapy” and “Targeted drugs” for ideas.
The Foods Library can complement your plan, including anti-metastatic strategies and metabolic health
In the Lifestyle section gathers fascinating evidence for diets and exercise
The PLANS section may have information from what others are doing and have learned

Non-Hodgkin

Help grow the community